Yaoxue Xuebao

Submission On

( Vol 60 , Issue 04 ) |

27 Dec 2025
Day
Hour
Min
Sec
Publish On

( Vol 60 , Issue 04 ) |

31 Dec 2025
Scopus Indexed (2026) scopus
ABCD Indexed (2025) scopus
scopus

Yaoxue Xuebao

Yaoxue Xuebao (ISSN:0513-4870) is a monthly peer-reviewed scopus-indexed journal from 1960, from 1962 to 1966, from 1979 to Present. The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements. The journal welcomes all kind of research/review/abstract papers regarding Pharmacology, Toxicology and Pharmaceutics, General Pharmacology and Toxicology and Pharmaceutics Biochemistry, Genetics and Molecular Biology and Molecular Medicine and so on.

Aim And Scope

Yaoxue Xuebao

Pharmacology

Toxicology and Pharmaceutics

General Pharmacology

Toxicology and Pharmaceutics Biochemistry

Genetics and Molecular Biology

Molecular Medicine

Latest Journal

Yaoxue Xuebao

  • YX-18-11-2024-2128
  • | Yaoxue Xuebao (ISSN:0513-4870)

Pharmacokinetics of wogonin-aloperine cocrystal in rats

Bexarotene (BEX), a specific retinoic acid X receptor (RXR) agonist granted by Food and Drug Administration (FDA) approval for the clinical treatment of T cell lymphoma, has now been found to exert pharmacological effects in the nervous system, with low bioavailability and poor cerebral distribution limiting its application in treatment on neurological disorders. Pharmaceutical co-crystal was a helpful method to improve the bioavailability and tissue distribution of active pharmaceutical ingredients (APIs). Here, 2bexarotene-ligustrazine (2BEX-LIG), a novel co-crystal system of BEX and ligu

read more..
  • YX-18-11-2024-2127
  • | Yaoxue Xuebao (ISSN:0513-4870)

Application progress of radiolabeling strategies in human mass balance studies

Human radiolabeled mass balance studies are an important component of the clinical pharmacology programs supporting the development of new investigational drugs. These studies allow for understanding of the absorption, distribution, metabolism, and excretion of the parent drug and metabolite(s) in the human body. Understanding the drug's disposition as well as metabolite profiling and abundance via mass balance studies can help inform the overall drug development program. A survey of the US Food and Drug Administration (FDA)‐approved new drug applications (NDAs) indicated that about 6

read more..
  • YX-18-11-2024-2126
  • | Yaoxue Xuebao (ISSN:0513-4870)

Advances of artificial intelligence technology in the discovery and optimization of lead compounds

Artificial intelligence (AI) encompasses a broad spectrum of techniques that have been utilized by pharmaceutical companies for decades, including machine learning, deep learning, and other advanced computational methods. These innovations have unlocked unprecedented opportunities for the acceleration of drug discovery and delivery, the optimization of treatment regimens, and the improvement of patient outcomes. AI is swiftly transforming the pharmaceutical industry, revolutionizing everything from drug development and discovery to personalized medicine, including target identification and

read more..
  • YX-18-11-2024-2125
  • | Yaoxue Xuebao (ISSN:0513-4870)

Design, synthesis and antidepressant activity of novel genipin derivatives

Genipin has been the focus of research as a multifunctional compound for the treatment of pathogenic diseases. However, hepatotoxicity caused by oral genipin raises concerns about its safety. To obtain novel derivatives with low toxicity and efficacy, we synthesized methylgenipin (MG), a new compound, using structural modification, and investigated the safety of MG administration. The results showed that the LD50 of oral MG was higher than 1000 mg/kg, no mice died or were poisoned during the experiment in the treatment group, and there was no significant difference in biochemical parameters

read more..
  • YX-18-11-2024-2124
  • | Yaoxue Xuebao (ISSN:0513-4870)

Advances in gastric retention drug delivery system

Oral absorption of drugs with narrow absorption window in the upper small intestine shows poor bioavailability with conventional dosage forms due short residence time. To overcome this restriction and to increase the bioavailability of these drugs, controlled drug delivery systems with a prolonged residence time in the stomach can be used. Gastric retention drug delivery system can be used to prolonged residence times of the drug in the upper part of the gastrointestinal tract. The current review deals with formulation developments of gastric retentive drug delivery systems which is prolong

read more..

The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements.

Information
Guidelines
Contact Us
  • journalpublication435@gmail.com
  • admin@yaoxuexuebao-05134870.com
  • support@yaoxuexuebao-05134870.com
All rights reserved | © 2024 Yaoxue Xuebao (ISSN:0513-4870).